Prognostic significance of PD-L1 and PD-L2 in breast cancer

Autor(es)

Baptista, Mauricio Z. ^[1] ; Sarian, Luis Otavio ^[1] ; Derchain, Sophie F. M. ^[1] ; Pinto, Glauce A. ^[2] ; Vassal, Jose ^[2]

Afiliação do(s) autor(es)

^[1] State Univ Campinas UNICAMP, Fac Med Sci, Womens Hosp CAISM, Dept Obstet & Gynecol, BR-13083970 Campinas, SP - Brazil

^[2] State Univ Campinas UNICAMP, Fac Med Sci, Womens Hosp CAISM, Lab Investigat & Mol Pathol LAPE, BR-13083970 Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: HUMAN PATHOLOGY; v. 47, n. 1, p. 78-84, JAN 2016.
• Citações Web of Science: 82

Resumo

PD-L1 and PD-L2 constitute an important antitumor immune response. In breast cancer, their prognostic value is still to be defined. In this study, we investigate the correlation between PD-L1 and PD-L2 protein expressions with clinical and pathologic features and disease-free survival and overall survival. To assess PD-L1 and PD-L2 expressions, we conducted immunohistochemistry studies using a breast cancer tissue microarray encompassing a total of 192 breast cancer cases, stages I, II, and III, with detailed clinical and outcome data. PD-L1 expression was present in 56.6% (107/189), and PD-L2 expression was identified in 50.8% (97/191) of breast cancer cases. Younger age at diagnosis, lymph node positivity, negative estrogen receptor, and recurrence at distant sites were all associated with both PD-L1 and PD-L2 expressions. The presence of larger tumors was associated only with PD-L1 expression. In our study, PD-L1 expression was significantly associated with better overall survival (P = .04) in breast cancer patients. Despite its association with poor clinical and pathologic features, PD-L1 expression emerges as a positive prognostic biomarker in breast cancer. This survival result might be due to the presence of a strong antitumor immune response leading to PD-L1 expression. (C) 2015 Elsevier Inc. All rights reserved. (AU)

• Processo FAPESP: 12/15059-8 - Avaliação de biomarcadores para detecção de neoplasia maligna em mulheres com tumor anexial
• Beneficiário: Sophie Françoise Mauricette Derchain
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 13/25683-3 - Comparação do perfil genômico de mulheres brasileiras e norte-americanas portadoras de câncer de mama receptor de estrógeno positivo/HER2 negativo
• Beneficiário: Luís Otávio Zanatta Sarian
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 08/02469-8 - Instabilidade genômica em neoplasias malignas da mama em função da presença do receptor de estrógeno e da concentração de alumínio intracelular
• Beneficiário: Luís Otávio Zanatta Sarian
• Modalidade de apoio: Auxílio à Pesquisa - Regular